Trium Capital Rejects Acelyrin (SLRN)-Alumis Merger, Urges Liquidation Instead
Key Summary: On April 29, 2025, Trium Capital opposes the Acelyrin-Alumis merger, citing undervaluation, flawed process, ignored alternatives, and conflicts of interest. They believe liquidation offers better value and urge a vote against the deal.
Market Cap: $247 million| Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
On April 29, 2025, Trium Capital LLP stated that it opposes the Acelyrin-Alumis merger, calling it value-destructive as it offers shareholders less than Acelyrin’s cash value. They argue liquidation would yield higher returns, criticize the biased and flawed deal process, highlight conflicts of interest, and note better offers were dismissed. Trium urges shareholders to vote against the merger. Source
Member discussion